Modality
Gene Editing
MOA
SOS1i
Target
RET
Pathway
Incretin
HNSCCTTR Amyloidosis
Development Pipeline
Preclinical
Aug 2019
→ Aug 2028
PreclinicalCurrent
NCT06629520
890 pts·TTR Amyloidosis
2019-08→2028-08·Terminated
890 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-112.4y awayInterim· TTR Amyloidosis
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Preclinical
Termina…
Catalysts
Interim
2028-08-11 · 2.4y away
TTR Amyloidosis
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06629520 | Preclinical | TTR Amyloidosis | Terminated | 890 | NT-proBNP |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| RHH-5389 | Roche | Preclinical | RET | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| REG-647 | Regeneron | Preclinical | SMN2 |